This brand name is authorized in Australia, New Zealand
The drug ZOLACOS contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Goserelin
UNII 0F65R8P09N - GOSERELIN
|
|
Goserelin is a synthetic analogue of naturally occurring LHRH. On chronic administration goserelin results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. |
|
2
Bicalutamide
UNII A0Z3NAU9DP - BICALUTAMIDE
|
|
Bicalutamide is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L02AE | Gonadotropin releasing hormone analogues | L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 9064C, 9065D, 9066E |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 13536, 13537 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
